Biotech | November 09, 2021
Bristol Myers neoadjuvant Opdivo (nivolumab) plus chemotherapy assists cancer patients effectively
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
